Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research focused on Pembrolizumab and Diffuse large B-cell lymphoma, with related work in Lymphoma, Oncology, Hepatitis B virus. Notable publications include 'Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas', 'Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma', and 'A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC'.
Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses
48 | NOVEL TRIPLET COMBINATION OF ORELABRUTINIB, LENALIDOMIDE, AND RITUXIMAB AS FRONTLINE THERAPY FOR MANTLE CELL LYMPHOMA: FINAL RESULTS OF POLARIS MULTICENTER PHASE II STUDY
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses
Significant alteration of protein profiles in a mouse model of polycystic ovary syndrome
ORELABRUTINIB‐LENALIDOMIDE‐RITUXIMAB (OLR) IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM PHASE 2 POLARIS STUDY IN CHINA
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC
Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s
Tumor CD73/A2aR adenosine immunosuppressive axis and tumor‐infiltrating lymphocytes in diffuse large B‐cell lymphoma: correlations with clinicopathological characteristics and clinical outcome
Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells